PROTEKT 39 countries Inactive Longitudinal Commercially Organism Hospital Susceptibility Telithromycin n/a (and (including AMR funded by data of common and comparator PROTEKT Australia) surveillance Sanofi-Aventis respiratory antimicrobial publications US)42–45, study (AMR pathogens from susceptibility 130, mechanisms patients with data and trends over time and respiratory geographic infections to region) telithromycin The 27 countries Inactive Longitudinal Commercially Organism Hospital Antimicrobial S. pneumoniae n/a Alexander AMR funded by susceptibility H. influenzae Project48, surveillance data for adults M. catarrhalis publications 130, 204, study with 207, 222, 223 respiratory (part of infections to a GAARD) range of compounds LIBRA n/a Inactive n/a Commercially n/a n/a Community and n/a n/a surveillance funded by nosocomial study Bayer infections publications (program or
PROTEKT (and PROTEKT US)42–45, 130, 39 countries (including Australia) Inactive Longitudinal AMR surveillance study (AMR mechanisms and trends over time and geographic region) Commercially funded by Sanofi-Aventis Organism Hospital Susceptibility data of common respiratory pathogens from patients with respiratory infections to telithromycin Telithromycin and comparator antimicrobial susceptibility data n/a publications The Alexander Project48, 130, 204, 207, 222, 223 (part of GAARD) 27 countries Inactive Longitudinal AMR surveillance study Commercially funded by Organism Hospital Antimicrobial susceptibility data for adults with respiratory infections to a range of compounds S. pneumoniae H. influenzae M. catarrhalis n/a publications LIBRA surveillance study (program or n/a Inactive n/a Commercially funded by Bayer n/a n/a Community and nosocomial infections n/a n/a publications
National-surveillance-and-reporting-of-antimicrobial-resistance-and-antibiotic-usage-for-human-health-in-Australia.docx